PEDIATRICS Vol. 95 No. 2 February 1995, pp. 286-294
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations

Committee on Drugs

These guidelines are designed to provide a format allowing for the protection of child subjects in drug research. Research involving children carries with it additional responsibilities for the investigator, IRB, and sponsor. The additional responsibilities should not be reasons for the pharmaceutical company, IRB, or the investigator to exclude children from drug research and its potential benefits. It is hoped that these guidelines foster an increase in the number of drug investigations carried out in children, thereby improving their health care.

The AAP believes it is unethical to deny children appropriate access to existing and new therapeutic agents. It is the combined responsibility of the pediatric community, pharmaceutical industry, and regulatory agencies to conduct the necessary studies; it is the responsibility of the general public to support the necessary research in order to assure that all children have access to important medications and receive optimal drug therapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Statement of reaffirmation:

AAP Publications Retired and Reaffirmed

Pediatrics 116: 796-796. [Full Text]

The following policy statement has been revised:

Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations
Pediatrics 60: 91-101.



This article has been cited by other articles:


Home page
Arch. Dis. Child.Home page
H Sammons
Ethical issues of clinical trials in children: a European perspective
Arch. Dis. Child., June 1, 2009; 94(6): 474 - 477.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
P. B. Smith, D. K. Benjamin Jr, M. D. Murphy, R. Johann-Liang, S. Iyasu, B. Gould, R. M. Califf, J. S. Li, and W. Rodriguez
Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity
Pediatrics, September 1, 2008; 122(3): e628 - e633.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. B. Smith, J. S. Li, M. D. Murphy, R. M. Califf, and D. K. Benjamin Jr
Safety of Placebo Controls in Pediatric Hypertension Trials
Hypertension, April 1, 2008; 51(4): 829 - 833.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. L. Berg
Ethical Challenges in Cancer Research in Children
Oncologist, November 1, 2007; 12(11): 1336 - 1343.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
S. P. Glasser, M. Salas, and E. Delzell
Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems
J. Clin. Pharmacol., September 1, 2007; 47(9): 1074 - 1086.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
S. S. Shah, M. Hall, D. M. Goodman, P. Feuer, V. Sharma, C. Fargason Jr, D. Hyman, K. Jenkins, M. L. White, F. H. Levy, et al.
Off-label Drug Use in Hospitalized Children
Arch Pediatr Adolesc Med, March 1, 2007; 161(3): 282 - 290.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. J. Bagley, W. W. Reynolds, and R. M. Nelson
Is a "Wage-Payment" Model for Research Participation Appropriate for Children?
Pediatrics, January 1, 2007; 119(1): 46 - 51.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
C. Stevens-Simon
Assent in Pediatric Research
Pediatrics, October 1, 2006; 118(4): 1800 - 1801.
[Full Text] [PDF]


Home page
PediatricsHome page
A. A. Kon
Assent in Pediatric Research
Pediatrics, May 1, 2006; 117(5): 1806 - 1810.
[Full Text] [PDF]


Home page
CLIN PEDIATRHome page
E. Y. Yoon, M. M. Davis, H. El-Essawi, and M. D. Cabana
FDA Labeling Status of Pediatric Medications
Clinical Pediatrics, January 1, 2006; 45(1): 75 - 77.
[PDF]


Home page
JAMAHome page
B. A. Brody, L. B. McCullough, and R. R. Sharp
Consensus and Controversy in Clinical Research Ethics
JAMA, September 21, 2005; 294(11): 1411 - 1414.
[Full Text] [PDF]


Home page
J Natl Cancer Inst MonogrHome page
J. A. Robertson
Cancer and Fertility: Ethical and Legal Challenges
J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 104 - 106.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
A. Whittle, S. Shah, B. Wilfond, G. Gensler, and D. Wendler
Institutional Review Board Practices Regarding Assent in Pediatric Research
Pediatrics, June 1, 2004; 113(6): 1747 - 1752.
[Abstract] [Full Text] [PDF]


Home page
Journal of Disability Policy StudiesHome page
V. H. Sharav
Conflicts of Interest in Biomedical Research Harm Children With and Without Disabilities
Journal of Disability Policy Studies, January 1, 2004; 15(1): 50 - 59.
[Abstract] [PDF]


Home page
HypertensionHome page
J. T. Flynn
Ethics of Placebo Use in Pediatric Clinical Trials: The Case of Antihypertensive Drug Studies
Hypertension, November 1, 2003; 42(5): 865 - 869.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. T Holdsworth
Pediatric Drug Research -- The Road Less Traveled
Ann. Pharmacother., April 1, 2003; 37(4): 586 - 591.
[Full Text] [PDF]


Home page
CLIN PEDIATRHome page
S. A. Gillman, M. Blatter, J. J. Condemi, M. Collins, A. O. Olufade, N. K. Leidy, D. Chapman, and B. Kramer
The Health-Related Quality of Life Effects of Once-Daily Cetirizine HCl Syrup in Children with Seasonal Allergic Rhinitis
Clinical Pediatrics, November 1, 2002; 41(9): 687 - 696.
[Abstract] [PDF]


Home page
NEJMHome page
R. Steinbrook
Testing Medications in Children
N. Engl. J. Med., October 31, 2002; 347(18): 1462 - 1470.
[Full Text] [PDF]


Home page
PediatricsHome page
K. L. Weise, M. L. Smith, K. J. Maschke, and H. L. Copeland
National Practices Regarding Payment to Research Subjects for Participating in Pediatric Research
Pediatrics, September 1, 2002; 110(3): 577 - 582.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
T. O. Erb, S. R. Schulman, and J. Sugarman
Permission and Assent for Clinical Research in Pediatric Anesthesia
Anesth. Analg., May 1, 2002; 94(5): 1155 - 1160.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. R. Botkin, E. Clayton, R. Nelson, B. Wilfond, M. A. Munger, F. G. Miller, A. F. Shorr, L. Friedman Ross, S. J. Fowler, B. J. Lipworth, et al.
Salmeterol and Inhaled Corticosteroids in Patients With Persistent Asthma
JAMA, December 26, 2001; 286(24): 3075 - 3078.
[Full Text] [PDF]


Home page
CLIN PEDIATRHome page
C. Berlin
Are We Losing Good Drugs?
Clinical Pediatrics, June 1, 2001; 40(6): 325 - 326.
[PDF]


Home page
American Journal of Medical QualityHome page
M. Seid, J. W. Varni, and P. S. Kurtin
Measuring Quality of Care for Vulnerable Children: Challenges and Conceptualization of a Pediatric Outcome Measure of Quality
American Journal of Medical Quality, July 1, 2000; 15(4): 182 - 188.
[Abstract] [PDF]


Home page
JAMAHome page
E. J. Emanuel, D. Wendler, and C. Grady
What Makes Clinical Research Ethical?
JAMA, May 24, 2000; 283(20): 2701 - 2711.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
J. M. Pellock
Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs
Pediatrics, November 1, 1999; 104(5): 1106 - 1116.
[Abstract] [Full Text]


Home page
PediatricsHome page
J. L. Blumer
Off-Label Uses of Drugs in Children
Pediatrics, September 1, 1999; 104(3): 598 - 602.
[Full Text]


Home page
PediatricsHome page
S. N. Cohen
The Pediatric Pharmacology Research Unit (PPRU) Network and Its Role in Meeting Pediatric Labeling Needs
Pediatrics, September 1, 1999; 104(3): 644 - 645.
[Full Text]


Home page
Arch Gen PsychiatryHome page
B. Vitiello and P. S. Jensen
Medication Development and Testing in Children and Adolescents: Current Problems, Future Directions
Arch Gen Psychiatry, September 1, 1997; 54(9): 871 - 876.
[Abstract] [PDF]


Home page
PediatricsHome page
Committee on Drugs
Alternative Routes of Drug Administration---Advantages and Disadvantages (Subject Review)
Pediatrics, July 1, 1997; 100(1): 143 - 152.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. L. Rehman, K. M. Sullivan, M. C. Walters, and K. Ohene-Frempong
Bone Marrow Transplantation for Sickle Cell Disease
N. Engl. J. Med., December 12, 1996; 335(24): 1845 - 1846.
[Full Text]


Home page
Journal of Health Politics, Policy and LawHome page
A. M. Dellinger
Subjected to Science: Human Experimentation in America before the Second World War.
Journal of Health Politics Policy and Law, March 1, 1996; 21(1): 159 - 166.
[PDF]


Home page
Journal of Health Politics, Policy and LawHome page
A. M. Dellinger
Children as Research Subjects: Science, Ethics, and Law.
Journal of Health Politics Policy and Law, March 1, 1996; 21(1): 159 - 166.
[PDF]